ArticleJournal of clinical laboratory analysis2026
Inflammation and Erythropoietin Resistance in Chronic Kidney Disease: A Cross-Sectional Study of C-Reactive Protein and Anemia in Hemodialysis Patients.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnemia represents a frequent complication in patients with chronic kidney disease (CKD) on hemodialysis. Inflammation results in disruption of erythropoiesis and establishment of less effective responses to erythropoiesis-stimulating agents (ESAs).
objectiveThis study investigated how systemic inflammation, which C-reactive protein (CRP) measured, relates to anemia severity and erythropoietin (EPO) responsiveness among patients with chronic kidney disease who undergo maintenance hemodialysis.
methodsCross-sectional study design involving 120 CKD patients. Participants were classified into high inflammation group for CRP levels at or above 10 mg/L and low inflammation group for CRP levels below 10 mg/L. Hematological parameters and iron status indices were analyzed, and weekly EPO doses were recorded. Pearson correlation and multivariable linear regression analyses were done while controlling for age, sex, comorbidities, and dialysis duration.
resultsHigh inflammation group displayed hematocrit level of 29.6% ± 4.8% while the control group showed a level of 34.2% ± 5.2% which produced a statistically significant difference (p < 0.001). CRP exhibited a negative correlation with hematocrit (r = -0.42, p < 0.001) and transferrin saturation (r = -0.36, p < 0.001) but showed a positive correlation with EPO dose (r = 0.48, p < 0.001). CRP established an independent relationship with hematocrit (β = -0.43, 95% CI: -0.58 to -0.28) and EPO dosage (β = 401, 95% CI: 210 to 592) during the multivariable analysis. LIMITATIONS: Cross-sectional design restricts causal relationships while the research team evaluated CRP as the only inflammatory marker.
conclusionsSystemic inflammation establishes a significant connection to anemia severity and EPO resistance, which affects CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.